discovermagazine - Learn how cats and humans can share key cancer mutations — and why those similarities could guide future treatment research.
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #oncology
Thursday, February 19, 2026, 9:23 pm / permalink 19449 / 3 stories in 24 days
discovermagazine - Learn more about the impact ultramarathon running has on red blood cells and how it may do more harm than good for the body.
Thursday, February 19, 2026, 4:23 pm / permalink 19438 / 3 stories in 25 days
medicalxpress - Researchers in China recently published a study in Science Translational Medicine describing a new antibody cocktail for protection against two common viruses. The proposed preventative treatment consists of antibodies identified in pediatricians who have…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #infanthealth
Thursday, February 19, 2026, 12:24 pm / permalink 19427 / 3 stories in 25 days
Zachary Brennan / endpoints - Top FDA officials said that a single pivotal trial requirement will be the “new default standard” for drug approvals, a move that goes beyond the agency’s prior discretion around not requiring two trials. In a ...
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda
Thursday, February 19, 2026, 11:24 am / permalink 19422 / 3 stories in 25 days
Jazmin Orozco Rodriguez / kffhealthnews - The state recently became the third to offer a public option health plan through its Affordable Care Act marketplace. But researchers said it’s unlikely to fill the gaps left by sweeping changes at the federal level.
#healthcare #publichealth #governmentpolicy
Thursday, February 19, 2026, 5:22 am / permalink 19405 / 5 stories in 25 days
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook 14 stories in 16.5 hours
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma 3 stories in 17.5 hours
Vitamin D trial shows reduced long‑COVID risk but no severity benefit 2 stories in 19.5 hours
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival 4 stories in 20.5 hours
FDA approves leucovorin for rare folate disorder despite autism hype 4 stories in 32.5 hours
HORMAD1 emerges as a potential target in triple‑negative breast cancer 4 stories in 45.5 hours
Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio 2 stories in 48.5 hours
Roche’s hoped‑for breast cancer pill fails crucial first‑line trial 5 stories in 49.5 hours
Novo Nordisk and Hims bury the hatchet and carve a deal 3 stories in 54.5 hours
AI improves UK breast-screening detection by about 10% 5 stories in 54.5 hours
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.
Bluesky: